American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 471-530 , September 2007

KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target

References 

  1. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  2. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  3. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis. 2006;47:738–750
  4. Macdougall IC, Temple RM, Kwan JT. Is early treatment of anaemia with epoetin-{alpha} beneficial to pre-dialysis chronic kidney disease patients? (Results of a multicentre, open-label, prospective, randomized, comparative group trial). Nephrol Dial Transplant. 2007;22:784–793
  5. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis. 2007;49:194–207
  6. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004;66:753–760
  7. Epogen (Epoetin alfa) for injection: Prescribing information. Silver Spring, MD, US Food and Drug Administration (USFDA), March 2007
  8. Procrit (Epoetin alfa) for injection: Prescribing information. Silver Spring, MD, US Food and Drug Administration (USFDA), March 2007
  9. Aranesp (darbepoetin alfa) for injection: Prescribing information. Silver Spring, MD, US Food and Drug Administration (USFDA), March 2007
  10. World Health Organization. WHOQOL: Measuring Quality of Life. Geneva, Switzerland: The World Health Organization Quality of Life Instruments; 1997;WHO/MSA/MNH/PSF/97.4
  11. Hahn EA, Cella D, Chassany O, et al: A comparison of the precision of health-related quality of life data relative to other clinical measures. Mayo Clin Proc (in press)
  12. Furuland H, Linde T, Ahlmen J, et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant. 2003;18:353–361
  13. Foley RN, Parfrey PS, Morgan J, et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int. 2000;58:1325–1335
  14. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584–590
  15. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol. 2005;16:2180–2189
  16. Pisoni RL, Bragg-Gresham JL, Young EW, et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis. 2004;44:94–111
  17. Ofsthun N, Labrecque J, Lacson E, Keen M, Lazarus JM. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney Int. 2003;63:1908–1914
  18. Levin A, Djurdjev O, Duncan J, Rosenbaum D, Werb R. Haemoglobin at time of referral, prior to dialysis predicts survival: An association of haemoglobin with long-term outcomes. Nephrol Dial Transplant. 2006;21:370–377
  19. Regidor DL, Kopple JD, Kovesdy CP, et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006;17:1181–1191
  20. Roberts TL, Foley RN, Weinhandl ED, Gilbertson DT, Collins AJ. Anaemia and mortality in haemodialysis patients: Interaction of propensity score for predicted anaemia and actual haemoglobin levels. Nephrol Dial Transplant. 2006;21:1652–1662
  21. Lacson E, Ofsthun N, Lazarus JM. Effect of variability in anemia management on hemoglobin outcomes in ESRD. Am J Kidney Dis. 2003;41:111–124
  22. Ofsthun NJ, Lazarus JM. Impact of the change in CMS billing rules for erythropoietin on hemoglobin outcomes in dialysis patients. Blood Purif. 2007;25:31–35
  23. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337–1343
  24. Berns JS, Elzein H, Lynn RI, et al. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003;64:1514–1521
  25. Greenwood RN, Ronco C, Gastaldon F, et al. Erythropoietin dose variation in different facilities in different countries and its relationship to drug resistance. Kidney Int Suppl. 2003;(Suppl 87):S78–S86
  26. Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis. 2005;46:799–811
  27. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial. J Am Soc Nephrol. 2004;15:148–156
  28. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007;369:381–388
  29. Kuriyama S, Tomonari H, Yoshida H, et al. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron. 1997;77:176–185
  30. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis. 1994;24:777–784
  31. Richardson D, Bartlett C, Will EJ. Optimizing erythropoietin therapy in hemodialysis patients. Am J Kidney Dis. 2001;38:109–117
  32. Tolman C, Richardson D, Bartlett C, Will E. Structured conversion from thrice weekly to weekly erythropoietic regimens using a computerized decision-support system: A randomized clinical study. J Am Soc Nephrol. 2005;16:1463–1470
  33. Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 2001;60:741–747
  34. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:110–118
  35. Abraham PA, Opsahl JA, Rachael KM, et al. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol. 1990;10:128–136
  36. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol. 1991;2:927–936
  37. Bahlmann J, Schoter KH, Scigalla P, et al. Morbidity and mortality in hemodialysis patients with and without erythropoietin treatment: A controlled study. Contrib Nephrol. 1991;88:90–106
  38. Berns JS, Rudnick MR, Cohen RM, et al. Effects of normal hematocrit on ambulatory blood pressure in epoetin-treated hemodialysis patients with cardiac disease. Kidney Int. 1999;56:253–260
  39. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis (Canadian Erythropoietin Study Group). BMJ. 1990;300:573–578
  40. Canadian Erythropoietin Study Group. Effect of recombinant human erythropoietin therapy on blood pressure in hemodialysis patients (Canadian Erythropoietin Study Group). Am J Nephrol. 1991;11:23–26
  41. Clyne N, Jogestrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron. 1992;60:390–396
  42. Furuland H, Linde T, Wikstrom B, et al. Reduced hemodialysis adequacy after hemoglobin normalization with epoetin. J Nephrol. 2005;18:80–85
  43. Kleinman KS, Schweitzer SU, Perdue ST, et al. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial. Am J Kidney Dis. 1989;14:486–495
  44. Laupacis A. Changes in quality of life and functional capacity in hemodialysis patients treated with recombinant human erythropoietin (The Canadian Erythropoietin Study Group). Semin Nephrol. 1990;10(suppl 1):S11–S19
  45. Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre-dialysis patients (A double-blind placebo-controlled trial). Ann Intern Med. 1989;110:108–114
  46. McMahon LP, McKenna MJ, Sangkabutra T, et al. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant. 1999;14:1182–1187
  47. McMahon LP, Mason K, Skinner SL, et al. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant. 2000;15:1425–1430
  48. Morris KP, Sharp J, Watson S, et al. Non-cardiac benefits of human recombinant erythropoietin in end stage renal failure and anaemia. Arch Dis Child. 1993;69:580–586
  49. Nissenson AR, Korbet S, Faber M, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol. 1995;5:1517–1529
  50. Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis. 1995;25:548–554
  51. Sikole A, Polenakovic M, Spirovska V, et al. Analysis of heart morphology and function following erythropoietin treatment of anemic dialysis patients. Artif Organs. 1993;17:977–984
  52. Suzuki M, Hirasawa Y, Hirashima K, et al. Dose-finding, double-blind, clinical trial of recombinant human erythropoietin (Chugai) in Japanese patients with end-stage renal disease (Research Group for Clinical Assessment of rhEPO). Contrib Nephrol. 1989;76:179–192discussion, 212-218
  53. Watson AJ, Gimenez LF, Cotton S, et al. Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med. 1990;89:432–435
  54. Moher D, Tsertsvadze A. Systematic reviews: When is an update an update?. Lancet. 2006;367:881–883
  55. Bucher HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users’ guides to the medical literature: XIX (Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group). JAMA. 1999;282:771–778
  56. National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47(suppl 3):S1–S145
  57. Uhlig K, Macleod A, Craig J, et al. Grading evidence and recommendations for clinical practice guidelines in nephrology (A position statement from Kidney Disease: Improving Global Outcomes (KDIGO)). Kidney Int. 2006;70:2058–2065
  58. Conlon PJ, Kovalik E, Schumm D, Minda S, Schwab SJ. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increased blood pressure. Ren Fail. 2000;22:432–444
  59. Coyne DW, Kapoian T, Suki W, et al. DRIVE Study Group Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975–984
  60. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490–1494
  61. Kunz K, Farquhar C: Grading and the GRADE instrument. Second Guidelines International Network Conference: Evidence in Action, Wellington, NZ, November, 2004

PII: S0272-6386(07)00934-1

doi: 10.1053/j.ajkd.2007.06.008

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 471-530 , September 2007

Article Tools

* Image Usage & Resolution